Hematopoietic stem cell transplantation in children with acute myeloid leukemia

острый миелоидный лейкоз у детей, трансплантация у детей, факторы риска, источники гемопоэтических стволовых клеток, осложнения

1. Locatelli F., Labopin M., Ortega J. Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. Blood 2003;101:1611—9.

2. Thomas X., Auglaret B., Thiebaut A. Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of alltrans retinoic acid therapy. Ann Hematol 1997;75:195—204.

3. Garderet L., Labopin M., Gorin N.C. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2005;105:405—9.

4. Swansbury G.J., Lawler S.D., Alimena G. et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia . Cancer Genet Cytogenet 1994;73(1):1—7.

5. Ferrant A., Doyen C., Delannoy A. Karyotype in acute myeloblastic leukemia: prognostic significance in a prospective study assessing bone marrow transplantation in first remission. Bone Marrow Transplant 1995;15(5):685—90.

6. Wheatley K., Burnett A., Gibson B. Optimising consolidation therapy: Four versus five courses SCT versus chemotherapy - preliminary results of MRC AML 12. Hematol J 2002;3:159—60.

7. Forman S., Schmidt G., Nademanee A. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 1991;9:1570—4.

8. Singhal S., Powles R., HensleeDowney P. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone Marrow Transplant 2002;29:291—5.

9. Godder K., Eapen M., Laver J.H. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol 2004;18:3798—804.

10. Lie S.O., Jonmundson G., Mellander L. A population-based study of 272 children with acute myeloid leukemia treated on two consecutive protocols with different intensity: best outcome in girls, infant and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 1996;94(1):82—8.

11. Ravindranath Y., Yeager A.M., Chang M.N. et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acutemyeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996;334(22):1428—34.

12. Woods W.G., Neudorf S., Gold S. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56—62.

13. Reiffers J., Stoppa A.M., Attal M. et al. Allogeneic versus autologous stem cell transplantation versus chemotherapy in patients with acute myeloid lеukеmia in first remission: the BGMT 87 study. Leukemia 1996;10(12):1874—82.

14. Michel G., Leverger G., Leblanc T. et al. Allogeneic bone marrow transplantation vs aggressive postremission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 1996;17(2):191—6.

15. Stevens R.F., Hann I.M., Wheatley K., Gray R.G. Marked improvement in outcome with chemotherapy alone in pediatric acute myeloid leukemia: results of the United Kingdom Medical research Council's 10 AML trial. MRC Childhood Leukemia Working Party. Br J Haematol 1998;101(1):130—40.

16. Klingebiel T., Pession A., Paolucci P., Rondelli R. Autologous versus allogeneic BMT in AML: the European experience. Report of EBMT- Pediatric disease Working party. Bone Marrow Transplant 1996;18(Suppl 2):49—52.

17. Thomas E.D., Buckner C.D., Clift R.A. et al Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979;301(11):597—9.

18. Srivastava A., Bradstock K.F., Szef J. et al. Busulfan and Melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 1993;12(14):323—9.

19. Cony-Makhoul P., Marit G., Boiron J.M. et al. Busulfan und melphalan prior autologous transplantation for myeloid malignancies. Bone Marrow Transplant 1995;16(1):69—70.

20. Bacigalupo A. Second EBMT workshop on reduced intensity conditioning regimen. Bone Marrow Transplant 2002;29(3):191—5.

21. Brenner M.K., Rill D.R., Moen R.C. et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341(8837):85—6.

22. Aversa F., Tabilio A., Terenzi A. et al. Successful engraftment of T-cell-depleted haploidentical «three-loci» incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84(11):3948—55.

23. Peters C., Matthes-Martin S., Fritsch G. et al. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia 1999;13(12):2070—8.

24. Handretinger R., Schumm M., Lang P. et al. Transplantation of megadoses of purified haploidentical stem cells. Ann NY Acad Sci 1999;872:351—61; discussion 361—2.

25. Gluckman E., Broxmeyer H.A., Auerbach A.D. et al. Hematopoietic reconstitution in patient with Fancomi anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 1989;321(17):1174—8.

26. Gluckman E., Rocha V., BoyerChammard A. et al. Outcome of cordblood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337(6):373—81.

27. Zhang Y., Li C., Jiang X. et al. Human placenta-derived mesenchymal progenitor cells support culture expansion of longterm culture-initiating cells from cord blood CD34+ cells. Exp Hematol 2004;32(7): 657—64.

28. McNiece I., Harrington J., Turney J. et al. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy 2004;6(4):311—7.

29. Rubinstein P.T., Stevens C.E. Placental blood for bone marrow replacement: the New York Blood Center's program and clinical results. Blood 2001;98:814а; abstr 3382.

30. Kalland T., Alm G., Stalhandshe T. Augmentations of mouse natural killer cell activity by LS 2626, a new immunomodulator. J Immunol 1985;134(6):3956—61.

31. Barnes D.W.H., Corp M.J., Loutit J.F. Treatment of murine leukemia with x rays and homologous bone marrow. BMJ 1956;ii:626.

32. Marmont A.M., Horowitz M.M., Gale R.P. et al. T-cell depletion of HLAidentical transplants in leukemia. Blood 1991;78(8):2120—30.

33. Weaver C.H., Clift R.A., Deeg H.J. et al. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 1994;14(6):885—93.

34. Choi S.J., Lee J.H., Kim S. et al. Treatment of relapse acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004;18(11):1789—97.

35. Levine J.E., Braun T., Penza S.L. et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic steam-cell transplantation. J Clin Oncol 2002;20(2):405—12.